Open innovation for phenotypic drug discovery: The PD2 assay panel.
about
An Overview of the Challenges in Designing, Integrating, and Delivering BARD: A Public Chemical-Biology Resource and Query Portal for Multiple Organizations, Locations, and DisciplinesInhibition of microglia activation as a phenotypic assay in early drug discoveryDrug repositioning approaches for the discovery of new therapeutics for Alzheimer's diseaseNovel Phenotypic Outcomes Identified for a Public Collection of Approved Drugs from a Publicly Accessible Panel of AssaysHigh-throughput fluorescence imaging approaches for drug discovery using in vitro and in vivo three-dimensional modelsSystematic Functional Characterization of Candidate Causal Genes for Type 2 Diabetes Risk Variants.Computational drug repositioning: from data to therapeutics.Perspective on the discovery and scientific impact of p38 MAP kinase.Antimalarial aminothiazoles and aminopyridines from phenotypic whole-cell screening of a SoftFocus(®) library.Identifying Small Molecules which Inhibit Autophagy: a Phenotypic Screen Using Image-Based High-Content Cell Analysis.Recent developments in cell-based assays and stem cell technologies for botulinum neurotoxin research and drug discoveryDiscovery of Novel Antiangiogenic Marine Natural Product Scaffolds.Systems pharmacology, pharmacogenetics, and clinical trial design in network medicineIndole diterpene alkaloids as novel inhibitors of the Wnt/β-catenin pathway in breast cancer cells.Collaboration versus outsourcing: the need to think outside the box.Targeting the pancreatic β-cell to treat diabetes.The marine-derived pachycladin diterpenoids as novel inhibitors of wild-type and mutant EGFR.The development of high-content screening (HCS) technology and its importance to drug discovery.High-content analysis to leverage a robust phenotypic profiling approach to vascular modulation.An Endothelial Cell/Mesenchymal Stem Cell Coculture Cord Formation Assay to Model Vascular Biology In Vitro.
P2860
Q26827563-E334A230-076E-4452-BD8D-D8437AE48A1FQ26996061-E985D59A-2C98-42E4-A967-A9FEE84BFFEFQ27024122-CFD03EA3-9AD3-4820-9844-7DAE6CAB7A6AQ28546583-D4B5EFCD-8B6F-4F65-BBCF-30E50AE817B4Q28834438-C2A73253-65FC-4077-9B5C-E67560EFB018Q30355101-E694237E-085B-4D82-99FB-EA75118390A9Q30594820-FC2C63FA-6F4A-4475-8819-9C69D2173295Q34360512-ACC74E94-1853-4696-B379-8802EAC822AFQ34509602-D08E1E69-253A-4318-8E22-D8F92326DDE8Q35111620-B1F2A427-7666-4F4B-A76C-545B8D96EB4BQ35772134-565E39EC-FF13-4620-8981-4B9C204AEB9EQ35957698-4C11064B-6C27-4EE5-93CB-9DCBD8520893Q37199477-593EF644-2A10-4BCB-BABF-4F2E2DB33C69Q37450146-0F3CA6F1-4731-4A24-9780-A59C2F8F6689Q37958064-260FE772-46B0-4952-9583-50301F8794B4Q38187862-74497F7A-8D84-4CFA-B025-5DD7508D8BABQ38726762-919F3885-0598-4915-A7C5-7780CCC723AEQ38772165-08459B76-062E-4A13-8FDD-BA44208B7415Q46568868-C281787A-1669-4717-9BF2-0C9FD94280B4Q50425407-0E850938-6849-4DF6-80F5-8D68B0549CBD
P2860
Open innovation for phenotypic drug discovery: The PD2 assay panel.
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Open innovation for phenotypic drug discovery: The PD2 assay panel.
@ast
Open innovation for phenotypic drug discovery: The PD2 assay panel.
@en
type
label
Open innovation for phenotypic drug discovery: The PD2 assay panel.
@ast
Open innovation for phenotypic drug discovery: The PD2 assay panel.
@en
prefLabel
Open innovation for phenotypic drug discovery: The PD2 assay panel.
@ast
Open innovation for phenotypic drug discovery: The PD2 assay panel.
@en
P2093
P356
P1476
Open innovation for phenotypic drug discovery: The PD2 assay panel.
@en
P2093
Alan D Palkowitz
Christopher M Moxham
Francis S Willard
Jennifer Oler
Jonathan A Lee
Karen L Cox
Rachelle J Sells Galvin
Robert B Peery
Saba Husain
Sarah E Oliver
P304
P356
10.1177/1087057111405379
P577
2011-04-26T00:00:00Z